Page last updated: 2024-08-25

methotrexate and Systemic Vasculitis

methotrexate has been researched along with Systemic Vasculitis in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Águeda, AF; Buttgereit, F; Cid, M; Dejaco, C; Hellmich, B; Luqmani, RA; Mahr, A; Monti, S; Ponte, C; Salvarani, C; Schmidt, W	1
Aït el Ghaz-Poignant, S; Bienvenu, B; Blockmans, D; Cohen, P; de Wazières, B; Diot, E; Fain, O; Godmer, P; Guillevin, L; Kyndt, X; le Berruyer, PY; Lidove, O; Mahr, A; Mouthon, L; Ninet, J; Pagnoux, C; Perrodeau, E; Puéchal, X; Quéméneur, T; Ravaud, P; Reny, JL; Rollot, F; Vanhille, P	1
Baltaro, R; Hurley, J; Sharma, P; Sharma, S	1
Gross, WL; Herlyn, K; Holle, JU; Schinke, S	1

Reviews

3 review(s) available for methotrexate and Systemic Vasculitis

Article	Year
Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD open, 2019, Volume: 5, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Biomarkers; Blindness; Drug Therapy, Combination; Female; Giant Cell Arteritis; Glucocorticoids; Humans; Male; Methotrexate; Observational Studies as Topic; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Recurrence; Risk Management; Systemic Vasculitis; Takayasu Arteritis	2019
Systemic vasculitis. American family physician, 2011, Mar-01, Volume: 83, Issue:5 Topics: Cyclophosphamide; Humans; Immunosuppressive Agents; Methotrexate; Systemic Vasculitis	2011
[Primary systemic vasculitides]. Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:8 Topics: Anti-Inflammatory Agents; Cyclophosphamide; Humans; Male; Methotrexate; Middle Aged; Prednisolone; Systemic Vasculitis; Treatment Outcome	2012

Trials

1 trial(s) available for methotrexate and Systemic Vasculitis

Article	Year
Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis & rheumatology (Hoboken, N.J.), 2015, Volume: 67, Issue:4 Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Remission Induction; Systemic Vasculitis; Treatment Outcome	2015

Article

Year

Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy.

Arthritis & rheumatology (Hoboken, N.J.), 2015, Volume: 67, Issue:4

Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Remission Induction; Systemic Vasculitis; Treatment Outcome

2015